Description
Global automated and rapid microbiological tests market analysis and insights
The global Automated and Rapid Microbiological Tests market estimated at US$6.8 billion in the year 2024 is now projected to grow at a CAGR of 7.36% and reach US$10.33 billion by 2030.
The automated and rapid microbiological tests market has been propelled by a convergence of factors that underscore its significance across various industries. One of the primary drivers is the relentless advancement in technology. Innovations in automation, molecular biology, and miniaturization have led to the development of sophisticated testing platforms that deliver swift and accurate results. This technological evolution has revolutionized industries such as healthcare, food safety, pharmaceuticals, and environmental monitoring. The demand for timely information in these sectors has further fueled the growth of automated and rapid microbiological tests.
The increasing emphasis on safety and quality has also been instrumental in driving market growth. Rapid testing methods enable swift detection of pathogens, preventing potential outbreaks and ensuring safety. Automated systems can significantly reduce the turnaround time for test results, facilitating prompt intervention. Moreover, regulatory agencies’ stringent requirements for quality control and assurance have accelerated the adoption of automated and rapid microbiological tests.
Emerging opportunities in point-of-care testing, integration of artificial intelligence and machine learning into automated testing systems, and customization and diversification of testing panels are likely to shape the market’s evolution over the forecast period. Additionally, the increasing global focus on environmental conservation offers growth prospects in the realm of environmental monitoring. As industries strive to minimize their ecological footprint, rapid and automated tests that swiftly identify pollutants and microbial imbalances in ecosystems will become indispensable tools for sustainable practices.
Automated and rapid microbiological tests market regional insights
North American automated and rapid microbiological tests market is expected to grow significantly over the forecast period 2024-2030. This growth can be attributed to the growing focus on drug and vaccine discovery and development, recent advances in biotechnology and pharmaceutical research and the presence of several market players offering a wide range of microbial testing products. United States contributed around 78% of the total North American automated and rapid microbiological tests market. It is estimated to have a market value of US$2.14 billion in the year 2024. Among the other noteworthy geographic markets are Canada and Mexico, each forecast to grow at 6.37% and 4.51% respectively over the 2024-2030 period.
Asia Pacific automated and rapid microbiological tests market is anticipated to witness an upsurge owing to the rapid industrialization and urbanization in the region. Economic stability, soaring demand for advanced healthcare facilities, and growth in disposable income are a few other factors contributing to the market growth in the region. China is expected to dominate the Asia-Pacific market and reach a market size of US$1.19 billion by 2030.
Within Europe, Germany, France, Italy and the U.K. are the key countries responsible for the significant growth of the regional market. Germany is expected to grow at a fastest CAGR of 5.72% over the forecast period.
Meanwhile, the Middle East & Africa is expected to show limited growth due to the strong presence of under-developed countries in Africa who are still struggling to meet technology standards. However, any growth that the region experiences is expected to come from developing Middle Eastern nations such as Qatar, U.A.E, and Oman due to a similar growth pattern as the Asia Pacific.
Key players
Key players profiled in the report include 3M Company; Abbott Laboratories, Inc.; Agilent Technologies, Inc.; Aidian Oy; Becton, Dickinson and Company; Beckman Coulter, Inc.; Biocartis NV; BioControl Systems, Inc.; bioMerieux SA; Biomerica, Inc.; Bio-Rad Laboratories, Inc.; Bruker Corp.; Cellabs Pty Ltd.; Cepheid Inc.; Danaher Corp.; Hologic, Inc.; MedMira Inc.; Merck KGaA; OraSure Technologies, Inc.; Oxoid Limited; QIAGEN N.V.; Quidel Corp.; Roche; Siemens Healthcare GmbH and Thermo Fisher Scientific Inc., among others.
Competitive landscape
August 28, 2023 – Danaher has entered into a definitive agreement to acquire protein consumables supplier Abcam for approximately $5.7 billion. Cambridge, UK-based Abcam offers antibodies, reagents, biomarkers, and assays for drug discovery, life sciences research, and diagnostics.
August 25, 2023 – Mirxes, a Singapore-headquartered developer of RNA-based tests for the early detection of cancer and other diseases, recently signed two agreements that will help advance the company’s commercial push into China and Indonesia.
Global Automated and rapid microbiological tests market scope
- By method
- Growth-based automated and rapid microbiological tests
- Viability-based automated and rapid microbiological tests
- Cellular component-based automated and rapid microbiological tests
- Nucleic acid-based automated and rapid microbiological tests
- Others
- By product category
- Instruments
- Consumables
- Plates and media
- Reagents and kits
- Microfluidic chips
- Others
- Software and services
- By application
- Clinical diagnostic
- Pharmaceutical and biotechnology
- Food & beverage testing
- Environmental testing
- Cosmetics & personal care
- Others
- By end user
- Laboratories
- Diagnostic laboratories
- Research laboratories
- Independent clinical laboratories
- Public health laboratories
- Others
- Hospitals and clinics
- Blood banks
- Pharmaceutical and biotechnology companies
- Food and beverage manufacturers
- Others
- Laboratories
- By region
- North America
- South America
- Europe
- Asia Pacific
- Middle East and Africa
| Report Attribute | Details |
| No. of Pages | 297 |
| Published | July-2025 |
| Forecast Period | 2024-2030 |
| Estimated Market Size in 2024 | US$6.8 billion |
| Forecasted Market Size by 2030 | US$10.33 billion |
| CAGR | 7.36% |
| Regions Covered | North America, South America, Europe, Asia Pacific, Middle East and Africa |
| Companies Mentioned | 3M Company; Abbott Laboratories, Inc.; Agilent Technologies, Inc.; Aidian Oy; Becton, Dickinson and Company; Beckman Coulter, Inc.; Biocartis NV; BioControl Systems, Inc.; bioMerieux SA; Biomerica, Inc.; Bio-Rad Laboratories, Inc.; Bruker Corp.; Cellabs Pty Ltd.; Cepheid Inc.; Danaher Corp.; Hologic, Inc.; MedMira Inc.; Merck KGaA; OraSure Technologies, Inc.; Oxoid Limited; QIAGEN N.V.; Quidel Corp.; Roche; Siemens Healthcare GmbH and Thermo Fisher Scientific Inc., among others. |
The research report provides a comprehensive review of market trends, market growth drivers, PEST Analysis, Market growth inhibitors, and strategic industry activities and SWOT Analysis of key players in the market.
The report provides market estimates and forecast for geographic markets such as the North America (US, Canada, Mexico and Rest of North America), South America (Brazil, Argentina and Rest of South America), Europe (Germany, France, U.K., Russia, Italy, Spain, Sweden, Netherlands, Poland, Austria, Norway, Switzerland, Denmark and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Taiwan, India, Australia and Rest of Asia-Pacific), Middle East (Iran, Turkey, Kuwait, UAE, Israel and Rest of Middle East) & Africa.
